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M A J O R A R T I C L E
Changes in Insulin Resistance After Initiation of
Raltegravir or Protease Inhibitors With Tenofovir-
Emtricitabine: AIDS Clinical Trials Group A5260s
Sahera Dirajlal-Fargo,1 Carlee Moser,2 Todd T. Brown,3 Theodoros Kelesidis,4 Michael P. Dube,5 James H. Stein,6 Judith Currier,4 and Grace A. McComsey1
1Department of Pediatric/Infectious Diseases and Rheumatology, Case Western Reserve University, Cleveland, Ohio; 2Harvard School of Public Health, Boston, Massachusetts; 3Department of
Medicine/Endocrinology and Metabolism, Johns Hopkins University, Baltimore, Maryland; 4Department of Medicine/Infectious Diseases, UCLA, Los Angeles, California; 5Department of Medicine,
University of Southern California Keck School of Medicine, Los Angeles; and 6Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison
Background. Antiretroviral therapy (ART) can alter glucose metabolism, but little data exist on the association of raltegravir
(RAL) with insulin resistance.
Methods. A5260s was a substudy of A5257, a prospective open-label randomized trial in which human immunodeficiency virus
(HIV)-infected treatment-naive participants were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir
(ATV/r), darunavir-ritonavir (DRV/r), or RAL over 96 weeks. Baseline and changes in insulin resistance as estimated by the homeo-
static model assessment of insulin resistance (HOMA-IR) were assessed. Wilcoxon rank-sum tests were used to assess shifts in the
distribution of fold increase from baseline between treatment arms, and Spearman correlation was used to assess associations be-
tween HOMA-IR and measures of inflammation and body composition.
Results. Three hundred twenty-eight participants were randomized; 90% were male, baseline median age was 36, HIV ribonu-
cleic acid copies were 4.55 log10 copies/mL, and CD4 cell count was 349/mm
3. Overall, HOMA-IR increased significantly after 4
weeks (1.9-fold change; 95% confidence interval, 1.73–2.05) then plateaued over the remainder of the study. Changes in HOMA-
IR were not different between the arms (P≥ .23). Changes in HOMA-IR were associated with changes in body mass index at weeks
48 and 96 (r = 0.12–0.22; P≤ .04). There was a trend with increases in HOMA-IR and increases in visceral abdominal fat at week 96
(r = 0.12; P = .06). At 48 and 96 weeks, HOMA-IR correlated with interleukin-6, high-sensitivity C-reactive protein, and soluble
CD163 (r = 0.16–0.27; P≤ .003).
Conclusions. Insulin resistance increased rapidly and then plateaued in treatment-naive participants initiating ART with TDF/
FTC, and no differences were found with RAL when compared with ATV/r or DRV/r.
Keywords. inflammatory markers; insulin resistance; raltegravir.
Disorders of glucose metabolism are common amongst human
immunodeficiency virus (HIV)-infected adults [1] with higher
prevalence noted in HIV-infected individuals compared with
healthy controls [2]. The mechanisms are likely multifactorial
including direct effects of HIV [3], antiretroviral therapy
(ART) [4, 5], inflammation [6], and traditional risk factors
[7]. Diabetes mellitus in this population can lead not only to
cardiovascular diseases (CVDs) [8], but it can also compound
other end organ dysfunctions associated with HIV such as
renal [9] and neurologic complications [10]. Exposure to nucle-
oside reverse-transcriptase inhibitors (NRTIs) (particularly the
thymidine analogs) [4, 5, 11] and protease inhibitors (PIs) [3, 12,
13] has been associated with an increase risk in diabetes and in-
sulin resistance. It has been hypothesized that changes in adi-
pose tissue (both central fat accumulation and peripheral
lipoatrophy) seen with NRTIs and PIs could mediate and con-
tribute to insulin resistance via lipotoxicity and mitochondrial
derangement [14, 15].
Little data exist on the effect of integrase inhibitors and spe-
cifically raltegravir (RAL) on glucose metabolism. A small, sin-
gle-arm, open-label study of 30 participants on RAL combined
with tenofovir/emtricitabine (TDF/FTC) reported no increase
in insulin resistance over 104 weeks [16]. Another study com-
paring patients on lopinavir/ritonavir plus RAL to lopinavir/ri-
tonavir plus NRTIs suggested no difference in insulin resistance
between the arms over 48 weeks [17].
The objective of the current study was to describe the changes
in insulin resistance over 96 weeks after initiating TDF/FTC
plus either atazanavir/ritonavir (ATV/r), darunavir/ritonavir
(DRV/r), or RAL in HIV-infected individuals naive to treat-
ment. We explored the time course and associations between
regional fat changes, body mass index (BMI), and insulin
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resistance because it is well known that adipose tissue plays a
role in glucose metabolism, and fat changes in HIV have been
associated with insulin resistance [14]. We also further exam-
ined the associations between markers of inflammation and im-
mune activation and insulin resistance over time.
METHODS
A5260s was a substudy of AIDS Clinical Trials Group (ACTG)
A5257 in which HIV-infected ART-naive participants ≥18
years of age with HIV-1 ribonucleic acid (RNA) ≥1000 cop-
ies/mL were randomized in an open-label fashion to receive
TDF/FTC (300 mg of TDF plus 200 mg of FTC) plus either
ATV/r (300 mg of ATV plus 100 mg of ritonavir once daily),
DRV/r (800 mg DRV plus 100 mg ritonavir once daily), or
RAL (400 mg twice daily). A5257 participants without known
CVD or diabetes mellitus, uncontrolled thyroid disease, or
use of lipid-lowering medications were eligible to enroll in
A5260s. Randomization was stratified by screening HIV-1
RNA level (>100 000 or ≤100 000 copies/mL) and Framingham
10-year CVD risk score (<6% risk or ≥6% risk). A5260s prima-
ry objectives were to compare atherosclerosis progression and
endothelial function between the randomized regimens [18],
and secondary objectives included assessing changes in immune
activation markers and body composition [19–21].A secondary
objective was to examine the effects of A5260s regimens on
markers of insulin resistance. The parent study and substudy
(clinicalTrials.gov NCT00811954 and NCT00851799) were ap-
proved by the Institutional Review Boards at participating insti-
tutions, and participants provided written informed consent.
Insulin Resistance Measure
Fasting glucose and insulin were measured at baseline and
weeks 4, 24, 48, and 96. Insulin resistance was estimated by ho-
meostasis model assessment-insulin resistance (HOMA-IR)
index [22]. The HOMA-IR was obtained using the following
calculation: log10 (HOMA-IR) = log10 (glucose (mg/dL) × log10
(insulin (IU)/405)). Insulin resistance was defined as HOMA-IR
>2.5.
Body Composition Measures
The BMI was measured at the same visits as insulin and glucose.
Substudy body scan evaluations occurred at baseline and week
96. Body composition was measured as previously detailed [20].
Single-slice computed tomography (CT) scan at the L4-L5 level
was used to quantify visceral adipose tissue (VAT), subcutane-
ous adipose tissue, and total adipose tissue. Scans were stan-
dardized and centrally read by blinded personnel at the Body
Composition Analysis Center at Tufts University (Boston,
MA) (DXA) and LA Biomed (Torrance, CA) (CT).
Laboratory Assessment
Blood samples (fasting for ≥8 hours) were collected. Serum in-
sulin was measured by commercial testing at Quest Diagnostics
by radioimmunoassay. Plasma biomarkers were measured at the
University of Vermont Laboratory for Clinical Biochemistry Re-
search Laboratory (Burlington, VT) on batched plasma samples
that were stored at −70°C degrees and not previously thawed,
and these included high-sensitivity C-reactive protein
(hsCRP) by nephelometry, D-dimer with immunoturbidimetric
methods, and soluble (s)CD14, sCD163, interleukin (IL)-6, by
enzyme-linked immunosorbent assay.
Statistical Analysis
The primary objective of this analysis was to determine the ex-
tent to which insulin resistance as measured by HOMA-IR
changed over time after initiating the randomized treatments
and to compare these changes between arms. The HOMA-IR
was transformed to the log10 scale for all analyses. Changes
over time in glucose are shown as median (interquartile range
[IQR]) absolute change from baseline for each study week;
changes over time in HOMA-IR are shown as median (IQR)
fold change from baseline; HOMA-IR results were back-
transformed for this calculation. Wilcoxon rank-sum tests
were used to assess shifts in the distribution of change from
baseline between treatment arms; P values were adjusted using
Benjamini-Hochberg methods to control false-discovery rate
(FDR) due to a multitude of biomarker assessments (some pre-
viously published [19]). Spearman rank correlations quantified
associations between HOMA-IR and body composition mea-
sures and with inflammatory markers; partial correlations were
used for adjusted comparisons. All pairwise-treatment group
comparisons were assessed with an FDR of 2.5%, and all other
comparisons were at a 5% alpha level. Analyses were conducted
as intent-to-treat (ITT); an as-treated secondary analysis showed
similar results to the ITT analysis (data not shown).
RESULTS
Baseline Characteristics and Disposition
As seen in Table 1, a total of 328 participants entered A5260s
(109 randomized to ATV, 106 to RAL, and 113 to DRV). Over-
all, median age was 36 years and 90% were male. The median
CD4 count was 349 cells/µL, HIV RNA copies 4.55 log10 cop-
ies/mL, BMI was 25 kg/m2, and VAT 72.9 cm2. Of the 328 par-
ticipants enrolled, 324 had HOMA-IR at baseline (107 in ATV
arm, 105 in RAL, and 112 in DRV). Median baseline HOMA-IR
was 0.59 and 10% of participants had HOMA-IR >2.5.
Changes in Homeostasis Model Assessment-Insulin Resistance and
Glucose Levels
The HOMA-IR increased rapidly from baseline to week 4 in all
3 treatment arms with a median (Q1, Q3) fold change of 2.05
(1.35, 3.45) on ATV/r, 1.95 (1.08, 2.78) on RAL, and 1.84 (1.14,
2.74) on DRV/r, and not different between the 2 PI arms
(P = .23) or between RAL and each of the PI/r arms (P≥ .32).
Overall, 22% of participants had HOMA-IR >2.5 at week
4. This rapid increase in HOMA-IR plateaued for the remainder
of the study in all treatment arms as seen in Table 2 and Figure 1
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with a median fold change of 1.75–2.06 for all study weeks and
no differences between arms (P≥ .18). The number of partici-
pants with abnormal HOMA-IR also did not increase for the
remainder of the study (24%–25% of participants had
HOMA-IR >2.5 through week 96). Glucose also increased by
week 4 with an absolute change of 3 (−2, 8) in the ATV/r
and RAL arms and 2 (−3, 7) in the DRV/r arm (P≥ .5 between
arms).
Linear regression analyses assessed association of baseline
factors including gender, age, viral load, CD4 count, and in-
flammation markers, with changes in HOMA-IR from baseline
to week 4 as well as changes from baseline to week 96. The only
baseline factor associated with change in HOMA-IR at week 4
was male gender (P = .005), whereas baseline male gender,
higher baseline sCD14, and higher baseline IL-6 were associated
with larger HOMA-IR change at week 96 (P≤ .04).
Changes in Homeostasis Model Assessment-Insulin Resistance
in Relation to Fat and Body Mass Index Changes
Although DXA scan was not performed at week 4, changes in
HOMA-IR seemed to occur much earlier than changes in fat
depots (see Figure 2). We have previously shown that all 3 reg-
imens were associated with similar increases in VAT by week 96
with a mean change of 25.8%. As shown in Figure 2, there was a
trend for a correlation between increases in HOMA-IR and in-
creases in VAT at week 96 (r = 0.12, P = .06). Changes in
HOMA-IR correlated with changes in total fat at week 96
(r = 0.17, P = .005). Changes in HOMA-IR modestly correlated
with changes in BMI only at week 48 (r = 0.12, P = .04) and
week 96 (r = 0.22, P = .005) (see Figure 3).
Association Between Inflammatory Markers and Homeostasis Model
Assessment-Insulin Resistance at Baseline and Weeks 48 and 96
As shown in Table 3, higher values of HOMA-IR at baseline
were associated with D-dimer at baseline (r = 0.14, P = .01)
Table 1. Baseline Characteristicsa
Characteristics ATV/r (n = 109) RAL (n = 106) DRV/r (n = 113)
Age (y) 37 (31–45) 36 (27–44) 35 (27–46)
Sex
M 99 (91%) 94 (89%) 101 (89%)
F 10 (9%) 12 (11%) 12 (11%)
Race/ethnicity
White 53 (49%) 43 (41%) 48 (42%)
Blacks 34 (31%) 34 (32%) 37 (33%)
Hispanics 20 (18%) 20 (19%) 25 (22%)
Current smoking 44 (40%) 39 (37%) 41 (36%)
Family history of diabetes 33 (30%) 22 (21%) 26 (23%)
CD4+ cell count (/mm3) 350 (211–461) 343 (185–445) 355 (207–461)
HIV-1 RNA (log10 copies/mL) 4.62 (4.05–5.10) 4.52 (4.13–5.08) 4.52 (3.95–4.95)
HIV-1 RNA
<100 000 copies/mL 78 (71%) 74 (69%) 86 (76%)
≥100 000 copies/mL 31 (29%) 32 (31%) 27 (24%)
Weight (kg) 80 (69–88) 77 (66–89) 77 (67–83)
Body mass index (kg/m2) 26 (23–29) 24 (22–28) 24 (22–27)
Visceral adipose tissue (cm2) 78.2 (42.6–111.3) 75.3 (41.6–110.1) 59.8 (32.8–99.2)
Glucose (mg/dL) 83 (77–91) 82 (76–91) 82 (78–88)
Insulin (µIU/dL) 3 (2–7) 3 (2–7) 2 (2–6)
HOMA-IR (log10) −0.21 (−0.40 to 0.18) −0.14 (−0.39 to 0.14) −0.33 (−0.41 to 0.12)
HOMA-IR >2.5 10 (9.4%) 9 (8.6%) 12 (10.7%)
Abbreviations: ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; HIV, human immunodeficiency virus; HOMA-IR, homeostatic model assessment of insulin resistance; RAL, raltegravir; RNA,
ribonucleic acid.
a Median values (interquartile range) or n (%).
Table 2. Median (IQR) Change From Baseline in Glucose and HOMA-IR
by Treatment Arm Over Timea
Glucose/HOMA-IR ATV/r RAL DRV/r
Glucose (mg/dL)
Week 4 3 (−2 to 8) 3 (−2 to 8) 2 (−3 to 7)
Week 24 4 (−1 to 8) 4 (0–10) 4 (−3 to 8)
Week 48 4 (−2 to 14) 4 (−2 to 10) 2 (−5 to 7)
Week 96 3 (−2 to 10) 6 (2–13) 2 (−2 to 8)
HOMA-IR
Week 4 2.05 (1.35–3.45) 1.95 (1.08–2.78) 1.84 (1.14–2.74)
Week 24 2.06 (1.30–3.39) 1.84 (1.13–2.69) 1.83 (1.05–2.71)
Week 48 1.96 (1.12–3.98) 1.75 (1.13–3.11) 1.83 (1.00–3.13)
Week 96 2.02 (1.10–3.06) 2.00 (1.08–3.32) 1.88 (1.01–2.92)
Abbreviations: ATV/r, atazanavir-ritonavir; DRV/r, darunavir/ritonavir; HOMA-IR, homeostatic
model assessment of insulin resistance; IQR, interquartile range; RAL, raltegravir.
a Glucose changes presented as median absolute changes. HOMA-IR changes presented as
fold changes.
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Figure 1. Changes in homeostatic model assessment of insulin resistance (HOMA-IR) over time by treatment arm. Median fold change in HOMA-IR from baseline by treat-
ment arm. Error bars represent interquartile range (IQR). Abbreviations: ATV/r, atazanavir-ritonavir; DRV/r, darunavir/ritonavir; RAL, raltegravir.
Figure 2. Association between change in homeostatic model assessment of insulin resistance (HOMA-IR) and change in fat depot. Median fold change from baseline
between HOMA-IR and visceral fat. Error bars represent interquartile range (IQR). Abbreviation: VAT, visceral adipose tissue.
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but not with other markers of systemic inflammation or mono-
cyte activation (P ≥ .06). In contrast, at weeks 48 and 96,
HOMA-IR was associated with weeks 48 and 96 hsCRP
(r = 0.24–0.27, P < .001), IL-6 (r = 0.18–0.27, P ≤ .003), and
with sCD163 (r = 0.16–0.19, P ≤ .008). After adjusting for pa-
rameters known to affect insulin resistance, such as age, sex,
BMI, and family history of diabetes, sCD163 still remained
associated with HOMA-IR after 96 weeks of ART (r = 0.14,
P = .026).
DISCUSSION
In this study, we show for the first time a significant and similar
increase in insulin resistance after 4 weeks of treatment with the
ritonavir-boosted PIs ATV and DRV compared with those
treated with the integrase inhibitor RAL. In addition, HOMA-
IR increases were most pronounced in the first 4 weeks and after
a longer duration of ART, correlated with several markers of
inflammation.
There is evidence that different PIs may differentially affect
glucose metabolism. Indinavir [23] and, in some studies [24]
but not all [25], LPV/r have been associated with insulin resis-
tance both in HIV-infected patients and in healthy subjects [23,
24]. On the other hand, ATV/r and DRV/r seem to have mini-
mal impact on insulin sensitivity both in HIV-infected and
HIV-negative subjects [24, 26–29]. In a smaller study, where
HIV-infected, treatment-naive patients were randomized to ei-
ther DRV/r (n = 28) or ATV/r (n = 27) with TDF/FTC, no sig-
nificant changes were seen in HOMA-IR from baseline at week
12 or 48 [26]. In the study presented here, participants random-
ized to either DRV/r or ATV/r regimens developed a rapid and
similar increase in HOMA-IR with a 2-fold increase by 4 weeks
of treatment. The baseline characteristics were similar between
the 2 studies, and the differences could be due to the smaller
Figure 3. Changes in homeostatic model assessment associated with changes in body mass index (BMI). Median fold change from baseline between homeostatic model
assessment of insulin resistance (HOMA-IR) and BMI. Error bars represent interquartile range (IQR).
Table 3. Baseline Factors Association With Baseline HOMA-IR (Log10)
Baseline Characteristics Spearman r P Value
Demographics and clinical parameter
Age 0.12 .04
BMI 0.33 <.001
HIV-specific factors
Baseline CD4 −0.07 .22
HIV RNA (log10 copies/mL) −0.01 .90
Markers of Inflammation and Immune Activation
Interleukin-6 0.10 .06
hsCRP 0.09 .13
D-Dimer 0.14 .01
sCD163 0.04 .46
sCD14 −0.06 .33
sIL-2 −0.04 .46
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; HOMA-IR,
homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive
protein; IL, interleukin; RNA, ribonucleic acid; s, soluble.
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number of participants. In addition, HOMA-IR slightly de-
creased in their study, but these changes are difficult to compare
because changes in HOMA-IR are reported as absolute change,
whereas we report fold change.
The RAL-containing regimen similarly impaired insulin sen-
sitivity as the boosted PI arms both in timing and in magnitude.
One possible hypothesis is that changes in HOMA-IR were the
result of TDF-FTC and not RAL or PIs. However, we have
shown that changes in insulin resistance were similar when
ART-naive participants were randomized to TDF/FTC or aba-
cavir/lamivudine-based regimen [30].
We had anticipated that increases in fat depots, specifically
VAT, which is most closely associated with insulin resistance,
would be correlated with increases in HOMA-IR. However,
changes in insulin resistance occurred early, after only 4
weeks of treatment, and was associated with changes in BMI
at 48 and 96 weeks. We hypothesize that (1) insulin resistance
is likely multifactorial and early changes are independent of fat
changes and (2) insulin resistance may lead to visceral fat by in-
hibiting lipolysis and early changes may be due to an alternate
mechanism either by direct inhibition of glucose transport [31]
as has been documented with PIs.
Another potential pathway for disorders of glucose metabo-
lism in HIV is via generalized inflammation [6]. Systemic in-
flammation as well as markers of immune activation sCD163
and sCD14 have been linked to insulin resistance in the general
population [32, 33]. We have previously shown that tumor ne-
crosis factor (TNF)α activation is linked to incident diabetes
after ART initiation in HIV-infected adults [6]; however, mark-
ers of monocyte activation were not measured in that study. The
HOMA-IR was not correlated with sCD14 in a study of HIV-
infected participants on ART [34]. In this trial, we found that
inflammatory markers IL-6 and hsCRP as well as marker of
monocyte activation sCD163 were associated with increase in
HOMA-IR after a longer duration of ART, but not before
ART. This is clinically relevant because these markers have
also been associated with CVD risk [35]. A novel finding is
our observed relationship between insulin resistance and the
marker of monocyte activation sCD163 in HIV-infected adults.
Soluble CD163 has been associated with HOMA-IR in healthy
adults [33]; in HIV, 1 study describes an association between ad-
iposity and sCD163, which was slightly decreased when adjust-
ing for insulin resistance [36]. It is interesting to note that there
was no correlation at baseline; however, even after adjusting for
variables known to affect insulin resistance, such as age, gender,
BMI, and family history of diabetes, sCD163 remained associ-
ated with HOMA-IR after 96 weeks of ART. Unlike what we
have found in our previous study in HIV-infected adults,
sTNFα receptors were not significantly correlated with insulin
resistance [6]. A potential explanation is that TNFα has a short
half-life unlike CD163-expressing macrophages. Microbial
translocation may also play a role in the association seen
between sCD163 and insulin resistance. Markers of microbial
translocation have been associated with insulin resistance [37]
and are known to stimulate the release of sCD163 [38].
Although the primary strength of our study is the random-
ized study design with 2 different boosted PI regimens and
RAL arms, there are several limitations. We recognize that the
majority of participants are not insulin resistant (with HOMA-
IR <2.5); however, it is well known that there is variability in the
threshold to define insulin resistance as HOMA-IR based on
age, gender and cardiometabolic risks [39]. Our cohort is rela-
tively young and predominantly male, and diabetics were ex-
cluded; therefore, these results may not be applicable to
women, older patients, in which the rates of insulin resistance
may be greater, or to those with diabetes. The clinical signifi-
cance of these changes in HOMA-IR is unclear; however, the
rapid and persistent 2-fold increase raises concerns that these
young participants may be at increased risk of developing ab-
normal glucose tolerance in the future. In addition, we used
HOMA-IR as a measure of insulin resistance as opposed to
the euglycemic-hyperinsulinemic clamp technique. However,
HOMA-IR has been shown to correlate with the euglycemic-
hyperinsulinemic clamp technique [40]. We did not collect in-
formation on dietary intake, which may affect insulin resistance.
Although fat changes were unlikely to occur very early, CT
scans were not obtained at week 4. There are no data describing
such acute VAT changes in HIV-infected adults on ART. Dube
et al [41] measured trunk fat at 16 weeks in HIV-infected adults
on ART and described a small increase (5%–7%).
CONCLUSIONS
In conclusion, we found that insulin resistance increased simi-
larly in RAL and boosted PI regimens, before an increase in
BMI and before the expected development of fat changes. Per-
sistent increase in insulin resistance after 48 and 96 weeks of
ART may be associated with systemic inflammation and im-
mune activation. The mechanisms that underlie the prompt im-
pairment of insulin sensitivity after starting ART require further
investigation.
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